News – Page 20 – Global Reach Health

February 17, 2023

Syfovre

February 17, 2023 – Apellis Pharmaceuticals, Inc. a global biopharmaceutical company and leader in complement, has announced that FDA has approved Syfovre^TM

February 16, 2023

Lamzede

February 16, 2023 - Chiesi Global Rare Diseases, (a business unit of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group, Chiesi Group)

February 3, 2023

<img width="480" height="360" src="https://sp-ao.shortpixel.ai/client/to_auto,q_glossy,ret_img,w_480,h_360/https://www.globalreachhealth.com/wp-content/uploads/2023/03/metastatic-hormone-recepter-reast-cancers-480x360.jpg" class="scale-with-grid wp-post-image" alt="metastatic-hormone-recepter-reast-cancers" decoding="async" />

metastatic-hormone-recepter-reast-cancers

FDA Approves Trodelvy ( sacituzumab govitecan-hziy) for patients with specific metastatic hormone recepter breast cancers having received endocrine-based therapy and at least two additional therapies.

February 3, 2023 - The Food and Drug Administration has approved sacituzumab govitecan-hziy

February 2, 2023

<img width="480" height="360" src="https://sp-ao.shortpixel.ai/client/to_auto,q_glossy,ret_img,w_480,h_360/https://www.globalreachhealth.com/wp-content/uploads/2023/02/fda-updates-480x360.jpg" class="scale-with-grid wp-post-image" alt="fda-updates" decoding="async" />

fda-updates

Other News and Announcements

February 02, 2023 - FDA Industry News: From Our Perspective – CDER’s Continued Efforts to Widen Naloxone Access
By: Marta Sokolowska, Ph.D., CDER Deputy Center Director for Substance Use and Behavioral Health

February 2, 2023

<img width="480" height="360" src="https://sp-ao.shortpixel.ai/client/to_auto,q_glossy,ret_img,w_480,h_360/https://www.globalreachhealth.com/wp-content/uploads/2023/02/CADD-System-480x360.png" class="scale-with-grid wp-post-image" alt="CADD-System" decoding="async" srcset="https://sp-ao.shortpixel.ai/client/to_auto,q_glossy,ret_img,w_480/https://www.globalreachhealth.com/wp-content/uploads/2023/02/CADD-System-480x360.png 480w, https://sp-ao.shortpixel.ai/client/to_auto,q_glossy,ret_img,w_300/https://www.globalreachhealth.com/wp-content/uploads/2023/02/CADD-System-300x225.png 300w, https://sp-ao.shortpixel.ai/client/to_auto,q_glossy,ret_img,w_1024/https://www.globalreachhealth.com/wp-content/uploads/2023/02/CADD-System-1024x768.png 1024w, https://sp-ao.shortpixel.ai/client/to_auto,q_glossy,ret_img,w_768/https://www.globalreachhealth.com/wp-content/uploads/2023/02/CADD-System-768x576.png 768w, https://sp-ao.shortpixel.ai/client/to_auto,q_glossy,ret_img,w_195/https://www.globalreachhealth.com/wp-content/uploads/2023/02/CADD-System-195x146.png 195w, https://sp-ao.shortpixel.ai/client/to_auto,q_glossy,ret_img,w_50/https://www.globalreachhealth.com/wp-content/uploads/2023/02/CADD-System-50x38.png 50w, https://sp-ao.shortpixel.ai/client/to_auto,q_glossy,ret_img,w_100/https://www.globalreachhealth.com/wp-content/uploads/2023/02/CADD-System-100x75.png 100w, https://sp-ao.shortpixel.ai/client/to_auto,q_glossy,ret_img,w_1200/https://www.globalreachhealth.com/wp-content/uploads/2023/02/CADD-System.png 1200w" sizes="(max-width:767px) 480px, 480px" />

CADD-System

Smiths Medical Recalls Certain CADD System Administration Sets and Cassette Reservoirs for Issues Causing Delay, Interruption, or Under-Delivery of Therapy

February 2, 2023 Smiths Medical is recalling certain CADD Administration Sets and Medication Cassette Reservoirs, used with the CADD ambulatory

February 2, 2023

<img width="480" height="360" src="https://sp-ao.shortpixel.ai/client/to_auto,q_glossy,ret_img,w_480,h_360/https://www.globalreachhealth.com/wp-content/uploads/2023/02/Tears-Lubricant-Eye-Drops-480x360.jpg" class="scale-with-grid wp-post-image" alt="Tears-Lubricant-Eye-Drops" decoding="async" srcset="https://sp-ao.shortpixel.ai/client/to_auto,q_glossy,ret_img,w_480/https://www.globalreachhealth.com/wp-content/uploads/2023/02/Tears-Lubricant-Eye-Drops-480x360.jpg 480w, https://sp-ao.shortpixel.ai/client/to_auto,q_glossy,ret_img,w_768/https://www.globalreachhealth.com/wp-content/uploads/2023/02/Tears-Lubricant-Eye-Drops-768x576.jpg 768w" sizes="(max-width:767px) 480px, 480px" />

Tears-Lubricant-Eye-Drops

Global Pharma Healthcare Issues Voluntary Nationwide Recall of Artificial Tears Lubricant Eye Drops Due to Possible Contamination

February 02, 2023 - Global Pharma Healthcare is voluntarily recalling all lots within expiry of their Artificial Tears Lubricant Eye Drops

February 1, 2023

<img width="480" height="360" src="https://sp-ao.shortpixel.ai/client/to_auto,q_glossy,ret_img,w_480,h_360/https://www.globalreachhealth.com/wp-content/uploads/2023/02/FDA-long-term-COVID-19-strategy-480x360.jpg" class="scale-with-grid wp-post-image" alt="FDA-long-term-COVID-19-strategy" decoding="async" srcset="https://sp-ao.shortpixel.ai/client/to_auto,q_glossy,ret_img,w_480/https://www.globalreachhealth.com/wp-content/uploads/2023/02/FDA-long-term-COVID-19-strategy-480x360.jpg 480w, https://sp-ao.shortpixel.ai/client/to_auto,q_glossy,ret_img,w_768/https://www.globalreachhealth.com/wp-content/uploads/2023/02/FDA-long-term-COVID-19-strategy-768x576.jpg 768w" sizes="(max-width:767px) 480px, 480px" />

FDA-long-term-COVID-19-strategy

FDA aims to ‘simplify’ vaccination with tweaks to long-term COVID-19 strategy

February 1, 2023 - The FDA has recognized it needs to make its vaccination messaging simple and clear moving forward. The COVID-19 pandemic has plagued America for nearly three years but the end might be in sight.

February 1, 2023

<img width="480" height="360" src="https://sp-ao.shortpixel.ai/client/to_auto,q_glossy,ret_img,w_480,h_360/https://www.globalreachhealth.com/wp-content/uploads/2017/02/New-Guidance-on-Acceptable-NDMA-and-NDEA-Levels-in-ARBs-480x360.jpg" class="scale-with-grid wp-post-image" alt="Global Reach Health" decoding="async" />

Global Reach Health

IBSA Pharma Inc. Issues Voluntary Nationwide Recall of Select Lots of TIROSINT® -SOL (levothyroxine sodium) Oral Solution Due to Subpotency

February 01, 2023 - IBSA Pharma Inc. is voluntarily recalling 27 lots of TIROSINT®-SOL (levothyroxine sodium) Oral Solution to the consumer level